(Q41714879)

English

Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method

scientific article published on 9 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

0 references

9

object named as

Atsushi Ochiai

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

2

object named as

Takeshi Kuwata

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

author name string

Eiji Higaki

1

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Akiko Kawano Nagatsuma

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Yasunori Nishida

4

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Takahiro Kinoshita

5

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Masaki Aizawa

6

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Hiroaki Nitta

7

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Masato Nagino

8

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

publication date

9 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

63-73

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

https://scigraph.springernature.com/pub.10.1007/s10120-014-0449-9

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

FGFR2 gene amplification and clinicopathological features in gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

The ERBB network: at last, cancer therapy meets systems biology.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0449-9

21 January 2018

A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurem

1 reference

https://pubmed.ncbi.nlm.nih.gov/25487305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25487305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10120-014-0449-9

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41714879&oldid=1926225083"